DMRA · Nasdaq · CIK 0001800315

Damora Therapeutics, Inc.

Damora Therapeutics, Inc.’s most recent SEC filing in our snapshot is a Form 4 filed on Sep 28, 2026. Its EDGAR record lists 17 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
—
Net income, FY2025
-$209.8M
Form 4 filings on record, past 12 months
17

Company overview

Legal name (as filed)
Damora Therapeutics, Inc.
Ticker
DMRA
SEC Central Index Key (CIK)
0001800315
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
WALTHAM, MA
State or country of incorporation
DE
Fiscal year ends
December 31
SEC filer category
Non-accelerated filer<br>Smaller reporting company
Position in SEC ticker list
#2250 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from Damora Therapeutics, Inc.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
n/aFY2021n/aFY2022n/aFY2023n/aFY2024n/aFY2025
Net income
-$51.8MFY2021-$61.6MFY2022-$38.3MFY2023-$21.4MFY2024-$209.8MFY2025
DMRA annual results
ItemFY2021
ended Dec 31, 2021		FY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
Revenue—————
Net income-$51.8M-$61.6M-$38.3M-$21.4M-$209.8M
Diluted EPS-$2.05-$2.43-$36.08-$18.53$3.98
Total assets$122.2M$73.2M$38.2M$17.1M$260.5M
Cash and equivalents$62.6M$32.8M$21.5M$14.2M$257.6M

XBRL tags used: netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

DMRA latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Mar 19, 202610-KAnnual report· period Dec 31, 2025Document · Index
Aug 10, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Jul 20, 20268-KMaterial agreement; Change to shareholder rights; Charter, bylaws or fiscal year change; Regulation FD disclosure· period Jul 16, 2026Document · Index
Apr 29, 2026DEF 14ADefinitive proxy statement· period Apr 29, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about Damora Therapeutics, Inc., by form type:

4 ×8S-8 POS ×88-K ×4SCHEDULE 13G/A ×43 ×3144 ×210-Q ×2SCHEDULE 13G ×2EFFECT ×1POSASR ×1POS AM ×18-A12B/A ×1ARS ×1DEF 14A ×1DEFA14A ×1
DMRA recent filings
FiledFormWhat it isOriginal
Sep 28, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 25, 2026Document · Index
Aug 13, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 12, 2026Document · Index
Aug 13, 20263Initial statement of beneficial ownership· period Aug 12, 2026Document · Index
Aug 12, 2026EFFECTEFFECTDocument · Index
Aug 10, 2026S-8 POSS-8 POSDocument · Index
Aug 10, 2026S-8 POSS-8 POSDocument · Index
Aug 10, 2026POSASRPOSASRDocument · Index
Aug 10, 2026S-8 POSS-8 POSDocument · Index
Aug 10, 2026S-8 POSS-8 POSDocument · Index
Aug 10, 2026S-8 POSS-8 POSDocument · Index
Aug 10, 2026S-8 POSS-8 POSDocument · Index
Aug 10, 2026S-8 POSS-8 POSDocument · Index
Aug 10, 2026S-8 POSS-8 POSDocument · Index
Aug 10, 2026POS AMPOS AMDocument · Index
Aug 10, 20268-A12B/A8-A12B/ADocument · Index
Aug 10, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Aug 6, 2026144Notice of proposed sale of securitiesDocument · Index
Jul 28, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Jul 20, 20268-KMaterial agreement; Change to shareholder rights; Charter, bylaws or fiscal year change; Regulation FD disclosure· period Jul 16, 2026Document · Index
Jul 7, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 3, 2026Document · Index
Jun 22, 2026144Notice of proposed sale of securitiesDocument · Index
Jun 17, 20268-KShareholder vote results· period Apr 28, 2026Document · Index
May 15, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
May 15, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
May 15, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
May 12, 202610-QQuarterly report· period Mar 31, 2026Document · Index
May 8, 20263Initial statement of beneficial ownership· period May 1, 2026Document · Index
May 4, 20268-KDirector or officer change· period Apr 28, 2026Document · Index
May 1, 2026ARSARS· period Dec 31, 2025Document · Index
Apr 29, 2026DEF 14ADefinitive proxy statement· period Apr 29, 2026Document · Index
Apr 29, 2026DEFA14AAdditional proxy soliciting materialsDocument · Index
Apr 23, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Apr 23, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Apr 20, 20268-KAuditor change· period Apr 17, 2026Document · Index
Apr 1, 20264Statement of changes in beneficial ownership (insider trade)· period Mar 30, 2026Document · Index
Apr 1, 20263Initial statement of beneficial ownership· period Mar 30, 2026Document · Index
Mar 25, 20264Statement of changes in beneficial ownership (insider trade)· period Mar 23, 2026Document · Index
Mar 25, 20264Statement of changes in beneficial ownership (insider trade)· period Mar 23, 2026Document · Index
Mar 25, 20264Statement of changes in beneficial ownership (insider trade)· period Mar 23, 2026Document · Index
Mar 25, 20264Statement of changes in beneficial ownership (insider trade)· period Mar 23, 2026Document · Index

Insider filing activity

17 Form 4 filings appear in Damora Therapeutics, Inc.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations· Companies headquartered in Massachusetts

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001800315 and XBRL company facts. Damora Therapeutics, Inc. on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.